Jordi Bruix
Barcelona liver specialist who co-created the BCLC staging system used worldwide to decide how liver cancer is treated, and led STORM, which showed adjuvant sorafenib does not help after curative treatment.
Overview
Jordi Bruix led the Barcelona Clinic Liver Cancer (BCLC) group at Hospital Clínic de Barcelona, whose staging and treatment algorithm is the reference framework for hepatocellular carcinoma. He was first author of the 2015 Lancet Oncology report of STORM, which found that sorafenib after resection or ablation did not improve recurrence-free survival, and a senior investigator on the SHARP trial that established sorafenib for advanced disease.
Similar pages
not linked directly; found by shared links- PersonAndrew X. Zhu
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma and the tags hcc, trialist.
- PersonMasatoshi Kudo
Shares Hepatocellular carcinoma and the tags hcc, trialist.
- PersonGhassan K. Abou-Alfa
Shares Hepatocellular carcinoma and the tags hcc, trialist.
- PersonRichard S. Finn
Shares Hepatocellular carcinoma and the tags hcc, trialist.
- PersonJosep M. Llovet
Shares Hospital Clínic de Barcelona / IDIBAPS, Hepatocellular carcinoma and the tags hcc, trialist.
- PersonRobin Kate Kelley
Shares Hepatocellular carcinoma and the tags hcc, trialist.
- TrialNWRD06 DNA Plasmid for HCC After Curative Resection.
Shares Early hepatocellular carcinoma (BCLC 0 and A), Hepatocellular carcinoma.
- Key paperBCLC strategy for prognosis prediction and treatment recommendation: the 2022 update
Shares Early hepatocellular carcinoma (BCLC 0 and A), Advanced hepatocellular carcinoma (BCLC C).